SBP GROUP Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity
I'm LongbridgeAI, I can summarize articles.SBP GROUPannounced preclinical data for its innovative drug TQF6422 at the 2026 European Congress on Obesity. TQF6422, a fully human monoclonal antibody targeting ActRII A/B, promotes muscle growth and fat reduction. Its in vitro activity exceeds comparable products by over 10 times. In combination with semaglutide, TQF6422 showed significant synergistic effects, increasing fat reduction by 1.5 to 2 times in an obese monkey model, with fat loss comprising 93% of total weight loss.
SBP GROUP (01177.HK) -0.050 (-0.885%) Short selling $43.14M; Ratio 14.151% announced that preclinical research data of its innovative drug TQF6422, an "ActRII A/B monoclonal antibody" independently developed by its subsidiary Chia Tai Tianqing, were presented at the 2026 European Congress on Obesity (ECO).
TQF6422 is a fully human monoclonal antibody targeting ActRII A/B. By specifically binding to ActRII A/B receptors and blocking ligand (Activin, Myostatin)-mediated signal transduction, it promotes skeletal muscle growth while enhancing lipolysis, thereby achieving dual effects of fat reduction and muscle gain.
The in vitro activity of TQF6422 is more than 10 times higher than that of comparable products. In combination therapy with semaglutide, TQF6422 demonstrated significant synergistic effects. In an obese monkey model, compared with semaglutide monotherapy, the combination regimen increased fat reduction by 1.5 times to 2 times, improved lean mass retention by 72% to 85%, and fat reduction accounted for 93% of total weight loss. (jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.)